Peter G Pappas Selected Research

Echinocandins

3/2024	Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
11/2023	Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
1/2023	Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.
1/2023	Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
10/2019	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
1/2019	Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis.
9/2011	Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.
8/2011	In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
11/2007	Combination antifungal therapy for the treatment of invasive yeast and mold infections.
10/2007	Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter G Pappas Research Topics

Disease

19	Mycoses (Diseases, Fungus) 03/2024 - 10/2003
16	Infections 12/2023 - 03/2003
15	Invasive Candidiasis 03/2024 - 06/2007
13	Candidemia 03/2024 - 05/2003
11	Invasive Fungal Infections 12/2022 - 02/2004
11	Cryptococcal Meningitis 01/2021 - 02/2004
10	Cryptococcosis 02/2024 - 01/2005
9	Aspergillosis 12/2022 - 01/2005
8	Candidiasis (Moniliasis) 08/2022 - 09/2005
7	Neoplasms (Cancer) 01/2017 - 06/2008
5	Acquired Immunodeficiency Syndrome (AIDS) 10/2015 - 06/2004
4	Blastomycosis 10/2023 - 04/2004
3	Histoplasmosis 01/2024 - 10/2008
3	Pneumonia (Pneumonitis) 01/2024 - 12/2011
3	Fungal Meningitis 09/2023 - 12/2013
3	Sepsis (Septicemia) 01/2019 - 07/2012
3	Neutropenia 01/2018 - 05/2003
3	Immune Reconstitution Inflammatory Syndrome 01/2016 - 09/2009
3	Meningoencephalitis 01/2016 - 02/2010
2	Hematologic Neoplasms (Hematological Malignancy) 10/2023 - 01/2015
2	Communicable Diseases (Infectious Diseases) 12/2022 - 03/2015
2	COVID-19 12/2022 - 12/2021
2	Fever (Fevers) 12/2022 - 03/2011
2	Central Nervous System Diseases (CNS Diseases) 10/2021 - 06/2010
2	Persistent Infection 01/2019 - 09/2011
1	Multiple Myeloma 12/2023
1	Coccidioidomycosis 10/2023
1	Endocarditis 01/2023
1	Disease Progression 12/2022
1	Melanoma (Melanoma, Malignant) 12/2022
1	Pulmonary Aspergillosis 12/2022
1	Exserohilum infection 06/2020
1	Osteomyelitis 01/2019
1	Fungemia 01/2019
1	Infectious Arthritis (Septic Arthritis) 01/2019
1	Crohn Disease (Crohn's Disease) 01/2019
1	Mucormycosis 07/2016
1	Brain Edema (Cerebral Edema) 01/2016
1	Multiple Sclerosis 01/2016
1	Blindness (Hysterical Blindness) 07/2014
1	Pancreatitis 05/2014

Drug/Important Bio-Agent (IBA)

18	Amphotericin B (Amphotericin)FDA LinkGeneric 10/2021 - 03/2003
13	Caspofungin (Cancidas)FDA Link 03/2024 - 10/2003
12	Fluconazole (Zonal)FDA LinkGeneric 01/2019 - 05/2003
11	EchinocandinsIBA 03/2024 - 01/2005
9	Antifungal AgentsIBA 06/2022 - 01/2005
8	Voriconazole (Vfend)FDA LinkGeneric 01/2023 - 10/2003
7	Micafungin (FK463)FDA Link 01/2019 - 10/2003
6	Sodium Glutamate (Accent)IBA 03/2024 - 06/2008
6	Itraconazole (Sporanox)FDA LinkGeneric 03/2024 - 03/2003
5	Flucytosine (Ancobon)FDA Link 10/2021 - 10/2003
5	Anidulafungin FDA Link 02/2014 - 10/2003
4	RezafunginIBA 03/2024 - 12/2021
4	Methylprednisolone FDA LinkGeneric 06/2020 - 06/2010
3	TriazolesIBA 09/2023 - 01/2005
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017 - 02/2014
3	liposomal amphotericin B FDA Link 02/2014 - 05/2005
2	Immunosuppressive Agents (Immunosuppressants)IBA 10/2023 - 05/2014
2	Anti-Bacterial Agents (Antibiotics)IBA 12/2022 - 05/2014
2	ibrexafungerpIBA 08/2022 - 10/2019
2	AntigensIBA 01/2021 - 05/2013
2	isavuconazoleIBA 01/2019 - 07/2016
2	Methylprednisolone Acetate (Depo-Medrol)FDA LinkGeneric 10/2015 - 12/2013
2	polyglucosanIBA 10/2015 - 09/2005
2	posaconazole FDA Link 07/2011 - 10/2003
1	EnzymesIBA 01/2024
1	Chimeric Antigen ReceptorsIBA 12/2023
1	galactomannanIBA 01/2023
1	Radioisotopes (Radionuclides)IBA 01/2023
1	Investigational DrugsIBA 08/2022
1	glucuronoxylomannanIBA 07/2022
1	laminaranIBA 07/2022
1	Immunoglobulin M (IgM)IBA 07/2022
1	Biomarkers (Surrogate Marker)IBA 06/2022
1	glucan synthaseIBA 10/2019
1	Terbinafine (Lamisil)FDA LinkGeneric 01/2017
1	ProdrugsIBA 07/2016
1	Natalizumab (Tysabri)FDA Link 01/2016
1	SolutionsIBA 10/2015

Therapy/Procedure

35	Therapeutics 12/2023 - 05/2003
4	Injections 06/2020 - 06/2013
3	Transplantation 01/2023 - 12/2002
3	Highly Active Antiretroviral Therapy (HAART) 07/2010 - 10/2008
2	Ambulatory Care (Outpatient Care) 01/2024 - 10/2023
2	Organ Transplantation 01/2017 - 01/2014
2	Cell Transplantation 01/2017 - 01/2015
2	Kidney Transplantation 02/2014 - 12/2002
1	Aftercare (After-Treatment) 02/2024
1	Epidural Anesthesia 09/2023
1	Combined Modality Therapy 01/2023
1	Artificial Respiration (Mechanical Ventilation) 12/2022
1	Immunomodulation 12/2021
1	Ventriculoperitoneal Shunt 06/2019
1	Central Venous Catheters 01/2019
1	Total Parenteral Nutrition 01/2019
1	Salvage Therapy 01/2019
1	Duration of Therapy 01/2018
1	Art Therapy 10/2015
1	Parenteral Nutrition 05/2014
1	Critical Care (Surgical Intensive Care) 05/2014